Bio-View Ltd (BIOV) - Total Assets
Based on the latest financial reports, Bio-View Ltd (BIOV) holds total assets worth ILA28.19 Million ILA (≈ $75.57K USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Bio-View Ltd - Total Assets Trend (2009–2024)
This chart illustrates how Bio-View Ltd's total assets have evolved over time, based on quarterly financial data. Also see BIOV market cap overview for the company's overall valuation and market capitalisation.
Bio-View Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Bio-View Ltd's total assets of ILA28.19 Million consist of 73.1% current assets and 26.9% non-current assets. Review Bio-View Ltd (BIOV) total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (ILA) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ILA0.00 | 24.5% |
| Accounts Receivable | ILA4.66 Million | 13.9% |
| Inventory | ILA8.35 Million | 24.8% |
| Property, Plant & Equipment | ILA0.00 | 0.0% |
| Intangible Assets | ILA0.00 | 0.0% |
| Goodwill | ILA0.00 | 0.0% |
Asset Composition Trend (2009–2024)
This chart illustrates how Bio-View Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See latest Bio-View Ltd stock price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Bio-View Ltd's current assets represent 73.1% of total assets in 2024, an increase from 0.0% in 2009.
- Cash Position: Cash and equivalents constituted 24.5% of total assets in 2024, down from 27.3% in 2009.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 3.0% in 2009.
- Asset Diversification: The largest asset category is inventory at 24.8% of total assets.
Bio-View Ltd Competitors by Total Assets
Key competitors of Bio-View Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
COCHLEAR LTD ADR 1/2/O.N.
F:OC50
|
Germany | €2.83 Billion |
|
TransMedics Group Inc
NASDAQ:TMDX
|
USA | $1.46 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.89 Billion |
|
Novocure Ltd
NASDAQ:NVCR
|
USA | $787.93 Million |
|
Shenzhen New Industries Biomedical
SHE:300832
|
China | CN¥9.58 Billion |
|
Jafron Biomedical Co Ltd
SHE:300529
|
China | CN¥5.20 Billion |
|
Hangzhou AGS MedTech Co. Ltd. A
SHG:688581
|
China | CN¥2.70 Billion |
|
Nanjing Vishee Medical Technology Co Ltd
SHG:688580
|
China | CN¥1.79 Billion |
Bio-View Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.60 | 2.89 | 3.44 |
| Quick Ratio | 1.58 | 2.17 | 2.84 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ILA11.38 Million | ILA22.08 Million | ILA16.50 Million |
Bio-View Ltd - Advanced Valuation Insights
This section examines the relationship between Bio-View Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.00 |
| Latest Market Cap to Assets Ratio | 0.61 |
| Asset Growth Rate (YoY) | -19.9% |
| Total Assets | ILA33.62 Million |
| Market Capitalization | $20.36 Million USD |
Valuation Analysis
Below Book Valuation: The market values Bio-View Ltd's assets below their book value (0.61x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Bio-View Ltd's assets decreased by 19.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Bio-View Ltd (2009–2024)
The table below shows the annual total assets of Bio-View Ltd from 2009 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ILA33.62 Million ≈ $90.14K |
-19.86% |
| 2023-12-31 | ILA41.95 Million ≈ $112.48K |
+0.06% |
| 2022-12-31 | ILA41.93 Million ≈ $112.41K |
+4.78% |
| 2021-12-31 | ILA40.02 Million ≈ $107.28K |
+18.08% |
| 2020-12-31 | ILA33.89 Million ≈ $90.86K |
-8.37% |
| 2019-12-31 | ILA36.98 Million ≈ $99.15K |
+10.70% |
| 2018-12-31 | ILA33.41 Million ≈ $89.57K |
-3.75% |
| 2017-12-31 | ILA34.71 Million ≈ $93.06K |
-10.32% |
| 2016-12-31 | ILA38.71 Million ≈ $103.77K |
+15.97% |
| 2015-12-31 | ILA33.38 Million ≈ $89.49K |
+7.24% |
| 2014-12-31 | ILA31.13 Million ≈ $83.45K |
+11.80% |
| 2013-12-31 | ILA27.84 Million ≈ $74.64K |
-6.65% |
| 2012-12-31 | ILA29.82 Million ≈ $79.96K |
+1.06% |
| 2011-12-31 | ILA29.51 Million ≈ $79.12K |
+37.51% |
| 2010-12-31 | ILA21.46 Million ≈ $57.54K |
+46.28% |
| 2009-12-31 | ILA14.67 Million ≈ $39.33K |
-- |
About Bio-View Ltd
Bio-View Ltd develops, manufactures, and markets automated cell imaging and analysis solutions for use in cytology, cytogenetic, and pathology clinical and research laboratories in Israel and internationally. The company's products include Accord, a workbench microscope station for semi-automated fluorescent imaging and analysis; Accord Plus, an automatic fluorescent imaging system that automatic… Read more